Is Bristol’s Long-Term Revenue Growth A Potential Salve For Celgene Shareholders?

 
• By Mandy Jackson

CEO Caforio used the J.P. Morgan stage to try to assuage Celgene investors who recently lost out on a $9 CVR under the buyout, playing up the long-term promise of the combined company. 

Sunshine
Without CVR cash, Celgene investors still could see an additional payout via BMS share buybacks and long-term sales growth • Source: Shutterstock

More from New Products

More from Scrip